Our Services
Medical Information
Helpful Resources
Published on: 10/22/2026
Yes, in most cases Ozempic (semaglutide) should be paused before surgery, and current anesthesia guidance generally suggests holding weekly injections for at least one week before a procedure to lower the risk of delayed stomach emptying, aspiration, and anesthesia complications. The exact timing depends on your dose, how long you have been on the medication, whether you take it for diabetes or weight loss, the type of anesthesia planned, and whether you still have nausea, vomiting, or fullness on the day of surgery. Some patients may be told to continue the drug while following a clear liquid diet, and blood sugar management may need separate adjustments, so there are several important factors to consider before stopping on your own. See the complete answer below for the specific hold times, fasting instructions, and warning signs that could cause your procedure to be delayed.
If you are unsure how your medication, symptoms, or upcoming procedure fit together, a free, instant symptom check can help you organize what you are feeling and understand which questions to raise with your surgeon or anesthesiologist next.
Last reviewed for medical accuracy: 10/22/2026
Undergoing surgery often means adjusting your medications. If you’re taking Ozempic (semaglutide) for type 2 diabetes or weight management, you might wonder, “do I have to stop Ozempic before surgery?” Here’s what you need to know, based on current guidelines and expert opinion.
• Ozempic is a once-weekly injectable GLP-1 receptor agonist.
• It helps lower blood sugar by:
Surgery can affect how medications work in your body:
• Fasting requirements. You often need to avoid food and drink for several hours before anesthesia. Ozempic’s impact on stomach emptying can increase the risk of nausea, vomiting, or aspiration (inhaling stomach contents).
• Blood sugar swings. Stress from surgery and changes in feeding can lead to low blood sugar (hypoglycemia) or high blood sugar (hyperglycemia).
• Fluid balance. Dehydration from fasting or from Ozempic’s GI side effects may complicate fluid management during and after surgery.
No single rule fits everyone. Guidance comes from drug manufacturers, professional societies, and your care team.
Manufacturer’s Label (Prescribing Information)
Endocrinology and Anesthesia Experts
Individualized Plan
Below is a general framework. Your plan may differ.
| Timing | Action |
|---|---|
| 1–2 weeks before OR | Evaluate GI side effects; ensure hydration |
| Night before surgery | Skip the weekly Ozempic dose if scheduled |
| Day of surgery | Do not take Ozempic; follow fasting rules |
| After surgery | Resume once you can eat/drink normally |
• Once you’re tolerating clear liquids without nausea, you can often restart Ozempic at your usual dose.
• Begin with small sips of water or clear fluids; ask when to advance to solid foods.
• Monitor blood sugar closely for 48–72 hours.
Maintain Hydration
• Drink clear liquids up to the allowed fasting window.
• Address any vomiting or diarrhea early.
Keep a Log
• Record your last Ozempic dose date/time.
• Note blood sugar readings, food intake, and symptoms.
Have Meds on Hand
• Fast-acting carbs (glucose tablets, juice) for lows.
• Backup diabetes meds if blood sugar rises.
Know Warning Signs
• Hypoglycemia: shakiness, sweating, confusion.
• Hyperglycemia: thirst, frequent urination, blurry vision.
If either feels severe, speak to a doctor right away.
Every person and surgery is unique. If you still wonder, “do i have to stop ozempic before surgery,” remember:
You might also consider a free, online symptom check, using the doctor approved Ubie Symptom Checker to get personalized guidance from home.
Managing Ozempic around surgery is about balancing risks: aspiration, nausea, and blood sugar swings versus rebound hyperglycemia. Clear communication and a tailored plan from your healthcare team will help minimize complications and keep your recovery on track.
If you have any serious or life-threatening symptoms—such as severe hypoglycemia, unrelenting vomiting, or signs of infection—speak to a doctor or go to the emergency department without delay. Always confirm any medication changes with your healthcare provider before making adjustments.
(References)
* Newsome PN, Buchholtz K, Cusi K, Linder M, Okanoue T, Ratziu V, Sanyal AJ, Sejling AS, Harrison SA, NN9931-4296 Investigators. A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis. N Engl J Med. 2021 Mar 25;384(12):1113-1124. doi: 10.1056/NEJMoa2028395. Epub 2020 Nov 13. PMID: 33185364.
* Melson E, Ashraf U, Papamargaritis D, Davies MJ. What is the pipeline for future medications for obesity? Int J Obes (Lond). 2025 Mar;49(3):433-451. doi: 10.1038/s41366-024-01473-y. Epub 2024 Feb 1. PMID: 38302593; PMCID: PMC11971045.
* Haseeb M, Chhatwal J, Xiao J, Jirapinyo P, Thompson CC. Semaglutide vs Endoscopic Sleeve Gastroplasty for Weight Loss. JAMA Netw Open. 2024 Apr 1;7(4):e246221. doi: 10.1001/jamanetworkopen.2024.6221. Epub 2024 Apr 1. PMID: 38607627; PMCID: PMC11015347.
* Jordan G, Young S, Alemán JO. Weight Loss Pharmacotherapy: Current and Future Therapies. Gastrointest Endosc Clin N Am. 2024 Oct;34(4):591-608. doi: 10.1016/j.giec.2024.06.006. PMID: 39277293; PMCID: PMC11407733.
* Docimo S Jr, Shah J, Warren G, Ganam S, Sujka J, DuCoin C. A cost comparison of GLP-1 receptor agonists and bariatric surgery: what is the break even point? Surg Endosc. 2024 Nov;38(11):6560-6565. doi: 10.1007/s00464-024-11191-1. Epub 2024 Sep 16. PMID: 39285034.
* Sanyal AJ, Newsome PN, Kliers I, Østergaard LH, Long MT, Kjær MS, Cali AMG, Bugianesi E, Rinella ME, Roden M, Ratziu V, ESSENCE Study Group. Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis. N Engl J Med. 2025 Jun 5;392(21):2089-2099. doi: 10.1056/NEJMoa2413258. Epub 2025 Apr 30. PMID: 40305708.
* Ciudin A, Johansson E, Zimner-Rapuch S, Dimitriadis GK, Bertrand M, Curteis T, Clark LJ, Fan L, Sapin H, Bergmann JF. Indirect comparative efficacy and safety of tirzepatide 10 and 15 mg versus semaglutide 2.4 mg for the management of obesity and overweight in patients with type 2 diabetes. Diabetes Obes Metab. 2025 Sep;27(9):4709-4719. doi: 10.1111/dom.16508. Epub 2025 Jun 19. PMID: 40537987; PMCID: PMC12326929.
* Hocking SL, Scott DA, Remedios ML, Horowitz M, Story DA, Greenfield JR, Boussioutas A, Devereaux B, Andrikopoulos S, Shaw JE, Olesnicky BL. 2025 ADS/ANZCA/GESA/NACOS clinical practice recommendations on the peri-procedural use of GLP-1/GIP receptor agonists. Anaesth Intensive Care. 2025 Sep;53(5):300-306. doi: 10.1177/0310057X251355288. Epub 2025 Aug 14. PMID: 40814081; PMCID: PMC12420935.
* Rubio-Herrera MA, Mera-Carreiro S. Weight management treatment in obesity. Med Clin (Barc). 2025 Nov;165(5):107152. doi: 10.1016/j.medcli.2025.107152. Epub 2025 Aug 26. PMID: 40865172.
* Sibal R, Balamurugan G, Langley J, Graham Y, Mahawar K. Macronutrient, Micronutrient Supplementation and Monitoring for Patients on GLP-1 Agonists: Can We Learn from Metabolic and Bariatric Surgery? Nutrients. 2025 Nov 23;17(23). doi: 10.3390/nu17233659. Epub 2025 Nov 23. PMID: 41373949; PMCID: PMC12693348.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.